MAP2K2 and lung adenocarcinoma: In multiple myeloma cells, YTHDF2 sustains proliferation through the STAT5A/MAP2K2/p-ERK pathway [28], while in lung adenocarcinoma cells, it promotes proliferation by targeting the AXIN1/WNT/β-catenin signalling pathway.